CORRECTING and REPLACING Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
18 Novembro 2021 - 4:45PM
Business Wire
Case series poster to be presented at the
Society for Neuro-Oncology Annual Meeting
Third paragraph, sixth sentence of release should read: CNSide
detected CSF tumor cells in all eleven measurements taken, compared
to six of eleven using cytology. (instead of CNSide detected CSF
tumor cells in all nine measurements taken, compared to five of
nine using cytology.)
The updated release reads:
BIOCEPT’S CNSIDE CEREBROSPINAL FLUID ASSAY
AIDS IN MONITORING TREATMENT RESPONSE AND DETECTS ACTIONABLE
BIOMARKERS IN PATIENTS WITH METASTATIC BREAST CANCER
Case series poster to be presented at the
Society for Neuro-Oncology Annual Meeting
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, today announced the
presentation of a multi-institutional case series showing that its
CNSide™ cerebrospinal fluid assay helps physicians monitor
treatment response and detects actionable mutations in patients
with metastatic breast cancer and leptomeningeal disease (LMD). The
poster will be presented virtually at the Society for
Neuro-Oncology Annual Meeting in Boston, Nov. 19, 2021, from
7:30-9:30 p.m. ET, and Biocept will be exhibiting at booth
#303.
Breast cancer is one of the most common cancers associated with
LMD, a devastating complication in which cancer spreads to the
membrane surrounding the brain and spinal cord. The current
standard of care for diagnosing LMD is through clinical evaluation,
imaging and cytology, which have limited sensitivity. Median
survival after a diagnosis of LMD is just two to three months.
The case series included four breast cancer patients, ages 32 to
57, with suspected LMD who were treated at four different
institutions. CNSide and cytology were used in parallel to detect
tumor cells in the cerebrospinal fluid at diagnosis and throughout
treatment. CNSide was also used to determine tumor cell counts and
the presence of HER2 amplification to help guide therapy. At
diagnosis, CNSide detected cancer cells in three of three patients,
compared with two of three patients for cytology. (The fourth
patient was diagnosed before CNSide was available.) CNSide detected
CSF tumor cells in all eleven measurements taken, compared to six
of eleven using cytology. Throughout treatment, CNSide showed a
decrease in CSF tumor cells in all four patients, ranging from
99.7% to 100%, corresponding with an improved clinical
response.
“Having a quantitative assay that provides tumor cell counts,
rather than just a positive or negative result, is a major advance
in the management of patients with leptomeningeal disease,” said
Priya Kumthekar, M.D., Neuro-Oncologist and Associate Professor of
Neurology at Northwestern Medicine’s Feinberg School of Medicine,
who will present the case series poster. “A positive cytology
result may suggest that the patient is not responding to treatment,
which could lead to therapy being stopped or changed. As this case
series shows, CNSide’s quantitative results may show that, in fact,
the tumor cell count has dropped dramatically, indicating that the
patient is responding, and therapy should be continued.”
“These cases illustrate the value of CNSide in treatment
response monitoring and identification of targets for therapy that
can produce a sustained response in leptomeningeal disease,” said
Michael Dugan, M.D., Chief Medical Officer and Medical Director of
Biocept. “CNSide has the potential to allow clinicians to have more
confidence in their treatment decisions, improving the clinical
management of leptomeningeal disease in a way that may help
patients see improvement in symptoms and live significantly longer
lives.”
The case series was completed by neuro-oncologists from Smilow
Cancer Hospital at Yale New Haven Health, Lou and Jean Malnati
Brain Tumor Institute at Northwestern Medicine, UT Southwestern
Medical Center and Barrow Neurological Institute. The abstract
(#BIOM-05), titled “Case Series of Multi-Institutional Utility of
CNSide™ to Manage Leptomeningeal Disease in Patients with
Metastatic Breast Cancer,” can be accessed here.
About Biocept
Biocept, Inc., develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information to aid in the diagnosis, treatment and monitoring of
patients with cancer. In addition to its broad portfolio of
blood-based liquid biopsy tests, the company has developed the
CNSide™ cerebrospinal fluid assay, designed to diagnose cancer that
has metastasized to the central nervous system. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide RT-PCR-based COVID-19 testing and services to support
public health efforts during this unprecedented pandemic. For more
information, visit www.biocept.com. Follow Biocept on Facebook,
LinkedIn and Twitter.
Forward-Looking Statements Disclaimer
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although Biocept believes that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, Biocept can
give no assurance that such expectations and assumptions will prove
to have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "could,"
"expect," or "believe" or the negative of these words or other
variations on these words or comparable terminology. To the extent
that statements in this release are not strictly historical,
including without limitation statements regarding the capabilities
and potential benefits of Biocept’s CNSide assay and the ability of
Biocept’s assays to provide physicians with clinically actional
information, such statements are forward-looking, and are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The reader is cautioned not to put
undue reliance on these forward-looking statements, as these
statements are subject to numerous risks and uncertainties,
including the risk that Biocept’s products and services may not
perform as expected. These and other risks are described in greater
detail under the "Risk Factors" heading of Biocept’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2021, filed
with the Securities and Exchange Commission (SEC) on November 15,
2021. The effects of such risks and uncertainties could cause
Biocept’s actual results to differ materially from the
forward-looking statements contained in this release. Biocept does
not plan to update any such forward-looking statements and
expressly disclaims any duty to update the information contained in
this press release except as required by law. Readers are advised
to review Biocept’s filings with the SEC, which can be accessed
over the Internet at the SEC's website located at www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211118005445/en/
Media Contact: Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301
Investor Contact: Jody Cain, LHA Investor Relations
Jcain@lhai.com, 310-691-7100
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024